COVID‑19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis (Review)

Albulescu,Radu; Dima,Simona Olimpia; Florea,Ioana Raluca; Lixandru,Daniela; Serban,Andreea Madalina; Aspritoiu,Veronica Madalina; Tanase,Cristiana; Popescu,Irinel; Ferber,Sarah

doi:10.3892/etm.2020.9324

COVID‑19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis (Review)

Authors:
- Radu Albulescu
- Simona Olimpia Dima
- Ioana Raluca Florea
- Daniela Lixandru
- Andreea Madalina Serban
- Veronica Madalina Aspritoiu
- Cristiana Tanase
- Irinel Popescu
- Sarah Ferber
View Affiliations

Affiliations: ‘Nicolae Cajal’ Institute, ‘Titu Maiorescu’ University, 004051 Bucharest, Romania, Fundeni Clinical Institute, 022328 Bucharest, Romania
Published online on: October 14, 2020 https://doi.org/10.3892/etm.2020.9324
Article Number: 194

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection and the caused disease ‑ coronavirus disease 2019 (COVID‑19), has affected so far >6,000,000 people worldwide, with variable grades of severity, and has already inflicted >350,000 deaths. SARS‑CoV‑2 infection seems severely affected by background diseases such as diabetes mellitus and its related complications, that seem to be favoring the most severe manifestations of SARS‑CoV‑2 and, therefore, require special attention in clinical care units. The present literature review focus on addressing several hypotheses explaining why diabetic patients could develop multi‑organ failure in severe acute respiratory syndrome coronavirus (SARS‑CoV) infections. Undoubtedly, as diabetes related complications are present it is expected to emphasize the severity of the COVID‑19. Dermatological complications can occur and worsen in diabetic patients, and diseases such as acanthosis nigricans and psoriasis are prone to more severe manifestations of COVID‑19. Approaches to treat SARS‑CoV‑2 infected patients, based on different solutions i.e. plasma therapy, use of antiviral compounds, development of vaccines or new therapeutic agents are ongoing.

View Figures

View References

1	Cui J, Li F and Shi ZL: Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 17:181–192. 2019.PubMed/NCBI View Article : Google Scholar
2	Hussain A, Bhowmik B and do Vale Moreira NC: COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 162(108142)2020.PubMed/NCBI View Article : Google Scholar
3	Gandhi RT, Lynch JB and Del Rio C: Mild or moderate covid-19. N Engl J Med: Apr 24, 2020 (Epub ahead of print). doi: 10.1056/NEJMcp2009249.
4	Ryan PM and Caplice NM: Is adipose tissue a reservoir for viral spread, immune activation and cytokine amplification in Coronavirus disease 2019. Obesity (Silver Spring). 28:1191–1194. 2020.PubMed/NCBI View Article : Google Scholar
5	Hodgson K, Morris J, Bridson T, Govan B, Rush C and Ketheesan N: Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology. 144:171–185. 2015.PubMed/NCBI View Article : Google Scholar
6	Allard R, Leclerc P, Tremblay C and Tannenbaum TN: Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 33:1491–1493. 2010.PubMed/NCBI View Article : Google Scholar
7	Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:271–280.e8. 2020.PubMed/NCBI View Article : Google Scholar
8	Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou M, Drakoulis N, et al: A new threat from an old enemy: Reemergence of coronavirus (Review). Int J Mol Med. 45:1631–1643. 2020.PubMed/NCBI View Article : Google Scholar
9	Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, et al: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 157(107843)2019.PubMed/NCBI View Article : Google Scholar
10	Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, et al: Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev: Mar 31, 2020 (Epub ahead of print). doi: 10.1002/dmrr.3319.
11	Odegaard JI and Chawla A: Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harb Perspect Med. 2(a007724)2012.PubMed/NCBI View Article : Google Scholar
12	Wang A, Zhao W, Xu Z and Gu J: Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 162(108118)2020.PubMed/NCBI View Article : Google Scholar
13	Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, Levitt KS, Oudit GY, Al-Omran M, Stewart DJ, et al: Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 295:H1377–H1384. 2008.PubMed/NCBI View Article : Google Scholar
14	Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR and Katze MG: Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 76:16–32. 2012.PubMed/NCBI View Article : Google Scholar
15	Kern L, Mittenbuhler MJ, Vesting AJ, Ostermann AL, Wunderlich CM and Wunderlich FT: Obesity-induced TNFα and IL-6 signaling: The missing link between obesity and inflammation-driven liver and colorectal cancers. Cancers (Basel). 11(24)2018.PubMed/NCBI View Article : Google Scholar
16	Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F, II Park DR, Pugin J, Skerrett SJ, Hudson LD and Martin TR: Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 164:1896–1903. 2001.PubMed/NCBI View Article : Google Scholar
17	Yiu HH, Graham AL and Stengel RF: Dynamics of a cytokine storm. PLoS One. 7(e45027)2012.PubMed/NCBI View Article : Google Scholar
18	Ruan Q, Yang K, Wang W, Jiang L and Song J: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46:846–848. 2020.PubMed/NCBI View Article : Google Scholar
19	Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426:450–454. 2003.PubMed/NCBI View Article : Google Scholar
20	Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, et al: Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 495:251–254. 2013.PubMed/NCBI View Article : Google Scholar
21	Liu F, Long X, Zhang B, Zhang W, Chen X and Zhang Z: ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 18:2128–2130.e2. 2020.PubMed/NCBI View Article : Google Scholar
22	Yousif MH, Dhaunsi GS, Makki BM, Qabazard BA, Akhtar S and Benter IF: Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol Res. 66:269–275. 2012.PubMed/NCBI View Article : Google Scholar
23	Zhang C, Zhao YX, Zhang YH, Zhu L, Deng BP, Zhou ZL, Li SY, Lu XT, Song LL, Lei XM, et al: Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc Natl Acad Sci USA. 107:15886–15891. 2010.PubMed/NCBI View Article : Google Scholar
24	Burns KD, Lytvyn Y, Mahmud FH, Daneman D, Deda L, Dunger DB, Deanfield J, Dalton RN, Elia Y, Har R, et al: The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. Am J Physiol Renal Physiol. 312:F335–F342. 2017.PubMed/NCBI View Article : Google Scholar
25	Gutta S, Grobe N, Kumbaji M, Osman H, Saklayen M, Li G and Elased KM: Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes. Am J Physiol Renal Physiol. 315:F263–F274. 2018.PubMed/NCBI View Article : Google Scholar
26	Wong TP, Ho KY, Ng EK, Debnam ES and Leung PS: Upregulation of ACE2-ANG-(1-7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: Implications for glucose transport. Am J Physiol Endocrinol Metab. 303:E669–E681. 2012.PubMed/NCBI View Article : Google Scholar
27	Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RI, Skyler JS, et al: Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 8:546–550. 2020.PubMed/NCBI View Article : Google Scholar
28	Bindom SM and Lazartigues E: The sweeter side of ACE2: Physiological evidence for a role in diabetes. Mol Cell Endocrinol. 302:193–202. 2009.PubMed/NCBI View Article : Google Scholar
29	Maddaloni E and Buzzetti R: Covid-19 and diabetes mellitus: Unveiling the interaction of two pandemics. Diabetes Metab Res Rev: Mar 31, 2020 (Epub ahead of print). doi: 10.1002/dmrr.3321.
30	Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M and Nagata N: TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol. 93:e01815–e1818. 2019.PubMed/NCBI View Article : Google Scholar
31	Limburg H, Harbig A, Bestle D, Stein DA, Moulton HM, Jaeger J, Janga H, Hardes K, Koepke J, Schulte L, et al: TMPRSS2 is the major activating protease of influenza a virus in primary human airway cells and influenza B virus in human type ii pneumocytes. J Virol. 93:e00649–19. 2019.PubMed/NCBI View Article : Google Scholar
32	Iacobellis G: COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Res Clin Pract. 162(108125)2020.PubMed/NCBI View Article : Google Scholar
33	Ceriello A, Stoian AP and Rizzo M: COVID-19 and diabetes management: What should be considered? Diabetes Res Clin Pract. 163(108151)2020.PubMed/NCBI View Article : Google Scholar
34	van der Zanden R, de Vries F, Lalmohamed A, Driessen JH, de Boer A, Rohde G, Neef C and den Heijer C: Use of dipeptidyl-peptidase-4 inhibitors and the risk of pneumonia: A population-based cohort study. PLoS One. 10(e0139367)2015.PubMed/NCBI View Article : Google Scholar
35	Gooßen K and Gräber S: Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetes Obes Metab. 14:1061–1072. 2012.PubMed/NCBI View Article : Google Scholar
36	Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, et al: Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 373:232–242. 2015.PubMed/NCBI View Article : Google Scholar
37	Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, et al: Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial. JAMA. 321:69–79. 2019.PubMed/NCBI View Article : Google Scholar
38	Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 369:1317–1326. 2013.PubMed/NCBI View Article : Google Scholar
39	White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 369:1327–1335. 2013.PubMed/NCBI View Article : Google Scholar
40	Carboni E and Carta AR: Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Med Hypotheses. 140(109776)2020.PubMed/NCBI View Article : Google Scholar
41	Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI and Gallagher PE: Effect of angiotensin- converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 111:2605–2610. 2005.PubMed/NCBI View Article : Google Scholar
42	Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S and Batlle D: ACE and ACE2 activity in diabetic mice. Diabetes. 55:2132–2139. 2006.PubMed/NCBI View Article : Google Scholar
43	Romani-Perez M, Outeirino-Iglesias V, Moya CM, Santisteban P, Gonzalez-Matias LC, Vigo E and Mallo F: Activation of the GLP-1 Receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology. 156:3559–3569. 2015.PubMed/NCBI View Article : Google Scholar
44	Wosten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, van Goor H, Kamilic J, Florquin S and Bos AP: Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol. 225:618–627. 2011.PubMed/NCBI View Article : Google Scholar
45	Zhang W, Xu YZ, Liu B, Wu R, Yang YY, Xiao XQ and Zhang X: Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. ScientificWorldJournal. 2014(603409)2014.PubMed/NCBI View Article : Google Scholar
46	Pfutzner A, Schondorf T, Hanefeld M and Forst T: High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: Effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol. 4:706–716. 2010.PubMed/NCBI View Article : Google Scholar
47	Drucker DJ: Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Meta. 27:740–756. 2018.PubMed/NCBI View Article : Google Scholar
48	Toki S, Goleniewska K, Reiss S, Zhang J, Bloodworth MH, Stier MT, Zhou W, Newcomb DC, Ware LB, Stanwood GD, et al: Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol. 142:1515–1528 e8. 2018.PubMed/NCBI View Article : Google Scholar
49	Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB and Kissow H: Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 154:4503–4511. 2013.PubMed/NCBI View Article : Google Scholar
50	Kahles F, Meyer C, Mollmann J, Diebold S, Findeisen HM, Lebherz C, Trautwein C, Koch A, Tacke F, Marx N and Lehrke M: GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes. 63:3221–3229. 2014.PubMed/NCBI View Article : Google Scholar
51	Lebherz C, Schlieper G, Mollmann J, Kahles F, Schwarz M, Brunsing J, Dimkovic N, Koch A, Trautwein C, Flöge J, et al: GLP-1 levels predict mortality in patients with critical illness as well as end-stage renal disease. Am J Med. 130:833–841.e3. 2017.PubMed/NCBI View Article : Google Scholar
52	Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, McNeilly AD, Balfour DJ, Savinko T, Fagerholm SC, et al: Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 119:652–665. 2016.PubMed/NCBI View Article : Google Scholar
53	Agarwal D, Schmader KE, Kossenkov AV, Doyle S, Kurupati R and Ertl HCJ: Immune response to influenza vaccination in the elderly is altered by chronic medication use. Immun Ageing. 15(19)2018.PubMed/NCBI View Article : Google Scholar
54	Saenwongsa W, Nithichanon A, Chittaganpitch M, Buayai K, Kewcharoenwong C, Thumrongwilainet B, Butta P, Palaga T, Takahashi Y, et al: Metformin-induced suppression of IFN-alpha via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes. Sci Rep. 10(3229)2020.PubMed/NCBI View Article : Google Scholar
55	Deshpande AD, Harris-Hayes M and Schootman M: Epidemiology of diabetes and diabetes-related complications. Phys Ther. 88:1254–1264. 2008.PubMed/NCBI View Article : Google Scholar
56	Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE and Ludvigsson J: Declining incidence of nephropathy in insulin- dependent diabetes mellitus. N Engl J Med. 330:15–18. 1994.PubMed/NCBI View Article : Google Scholar
57	Harris MI, Klein R, Welborn TA and Knuiman MW: Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 15:815–819. 1992.PubMed/NCBI View Article : Google Scholar
58	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
59	Valizadeh RBA, Mirzazadeh A and Bhaskar LVKS: Coronavirus-nephropathy; renal involvement in COVID-19. J Renal Inj Prev. 9(e18)2020.
60	Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579:270–273. 2020.PubMed/NCBI View Article : Google Scholar
61	Faubel S and Edelstein CL: Mechanisms and mediators of lung injury after acute kidney injury. Nat Rev Nephrol. 12:48–60. 2016.PubMed/NCBI View Article : Google Scholar
62	Wang H and Ma S: The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med. 26:711–715. 2008.PubMed/NCBI View Article : Google Scholar
63	Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, Al-Omari A, Hajeer AH, Senga M, Denison MR, et al: Middle East respiratory syndrome. N Engl J Med. 376:584–594. 2017.PubMed/NCBI View Article : Google Scholar
64	Desforges M, Le Coupanec A, Brison E, Meessen-Pinard M and Talbot PJ: Human respiratory coronaviruses: Neuroinvasive, neurotropic and potentially neurovirulent pathogens. Virologie (Montrouge). 18:5–16. 2014.PubMed/NCBI View Article : Google Scholar
65	Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, et al: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 77:1–9. 2020.PubMed/NCBI View Article : Google Scholar
66	Maiocchi S, Alwis I, Wu MCL, Yuan Y and Jackson SP: Thromboinflammatory functions of platelets in ischemia-reperfusion injury and its dysregulation in diabetes. Semin Thromb Hemost. 44:102–113. 2018.PubMed/NCBI View Article : Google Scholar
67	Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M and Garip T: The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications. 23:89–94. 2009.PubMed/NCBI View Article : Google Scholar
68	Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, et al: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 54:2430–2435. 2005.PubMed/NCBI View Article : Google Scholar
69	Vaidyula VR, Boden G and Rao AK: Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 17:577–585. 2006.PubMed/NCBI View Article : Google Scholar
70	Schneider DJ: Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 32:525–527. 2009.PubMed/NCBI View Article : Google Scholar
71	Fang L, Karakiulakis G and Roth M: Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 8(e21)2020.PubMed/NCBI View Article : Google Scholar
72	Wan Y, Shang J, Graham R, Baric RS and Li F: Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J Virol. 94:e00127–e00220. 2020.PubMed/NCBI View Article : Google Scholar
73	Hubert HB, Feinleib M, McNamara PM and Castelli WP: Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 67:968–977. 1983.PubMed/NCBI View Article : Google Scholar
74	Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF and Folsom AR: Cardiovascular risk factors and venous thromboembolism incidence: The longitudinal investigation of thromboembolism etiology. Arch Intern Med. 162:1182–1189. 2002.PubMed/NCBI View Article : Google Scholar
75	Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W, et al: Lung pathology of fatal severe acute respiratory syndrome. Lancet. 361:1773–1778. 2003.PubMed/NCBI View Article : Google Scholar
76	Chen J and Subbarao K: The immunobiology of SARS^*. Annu Rev Immunol. 25:443–472. 2007.PubMed/NCBI View Article : Google Scholar
77	Kalliolias GD and Ivashkiv LB: Overview of the biology of type I interferons. Arthritis Res Ther. 12 (Suppl 1)(S1)2010.PubMed/NCBI View Article : Google Scholar
78	Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, Nicholls JM, Peiris JS and Lau YL: Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 106:2366–2374. 2005.PubMed/NCBI View Article : Google Scholar
79	Okabayashi T, Kariwa H, Yokota S, Iki S, Indoh T, Yokosawa N, Takashima I, Tsutsumi H and Fujii N: Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol. 78:417–424. 2006.PubMed/NCBI View Article : Google Scholar
80	Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, Ye L, Xu S, Sun R, Wang Y and Lou J: Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 72:4410–4415. 2004.PubMed/NCBI View Article : Google Scholar
81	Lo AW, Tang NL and To KF: How the SARS coronavirus causes disease: Host or organism? J Pathol. 208:142–151. 2006.PubMed/NCBI View Article : Google Scholar
82	Choi G, Schultz MJ, Levi M and van der Poll T: The relationship between inflammation and the coagulation system. Swiss Med Wkly. 136:139–144. 2006.PubMed/NCBI
83	Bester J and Pretorius E: Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep. 6(32188)2016.PubMed/NCBI View Article : Google Scholar
84	Gupta R, Ghosh A, Singh AK and Misra A: Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 14:211–212. 2020.PubMed/NCBI View Article : Google Scholar
85	Lixandru D BE, Vîrgolici B, Vîrgolici H, Alexandru P, Băcanu ME, Gagniuc P, Ionescu-Tîrgovişte C and Serafinceanu C: Changes in the serum proinflammatory cytokines in patients with elevated HOMA-IR and type 2 diabetes mellitus. Farmacia. 63:132–139. 2015.
86	Kalus AA CA and Oleraud JE: Diabetes mellitus and other endocrine diseases. In: Fitzpatrick's Dermatology in General Medicine. Goldsmith LA, Katz S, Gilchrest BA, Paller AS, Leffel DJ and Wolff K (eds.). McGrawHill, New York, NY, 2012.
87	Popa ML, Popa AC, Tanase C and Gheorghisan-Galateanu AA: Acanthosis nigricans: To be or not to be afraid. Oncol Lett. 17:4133–4138. 2019.PubMed/NCBI View Article : Google Scholar
88	Hud JA Jr, Cohen JB, Wagner JM and Cruz PD Jr: Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol. 128:941–944. 1992.PubMed/NCBI
89	Duff M, Demidova O, Blackburn S and Shubrook J: Cutaneous manifestations of diabetes mellitus. Clin Diabetes. 33:40–48. 2015.
90	Khalid U, Hansen PR, Gislason GH, Lindhardsen J, Kristensen SL, Winther SA, Skov L, Torp-Pedersen C and Ahlehoff O: Psoriasis and new-onset diabetes: A Danish nationwide cohort study. Diabetes Care. 36:2402–2407. 2013.PubMed/NCBI View Article : Google Scholar
91	Conforti C, Giuffrida R, Dianzani C, Di Meo N and Zalaudek I: COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther: Mar 11, 2020 (Epub ahead of print). doi: 10.1111/dth.13298.
92	Tesch M: Spinal claudication and malum perforans pedis. Late sequela of ankylosing spondylitis (Bechterew disease) with cystic lumbosacral arachnopathy. Der Nervenarzt. 65:874–877. 1994.PubMed/NCBI(In German).
93	Begolli Gerqari A, Ferizi M, Halimi S, Aferdita Daka A, Hapciu S, Begolli I, Begolli M and Gerqari I: Malum perforans pedis - case report. Sci J Clin Med. 5:29–31. 2016.
94	Spravchikov N, Sizyakov G, Gartsbein M, Accili D, Tennenbaum T and Wertheimer E: Glucose effects on skin keratinocytes: Implications for diabetes skin complications. Diabetes. 50:1627–1635. 2001.PubMed/NCBI View Article : Google Scholar
95	Recalcati S: Cutaneous manifestations in COVID-19: A first perspective. J Eur Acad Dermatol Venereol. 35:e212–e213. 2020.PubMed/NCBI View Article : Google Scholar
96	Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM and Grazzini G: Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus. 14:152–157. 2016.PubMed/NCBI View Article : Google Scholar
97	Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 395:507–513. 2020.PubMed/NCBI View Article : Google Scholar
98	Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, et al: Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 117:9490–9496. 2020.PubMed/NCBI View Article : Google Scholar
99	Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F, Vinceti M, et al: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med. 46:3–16. 2020.PubMed/NCBI View Article : Google Scholar
100	Kickbusch I and Leung G: Response to the emerging novel coronavirus outbreak. BMJ. 368(m406)2020.PubMed/NCBI View Article : Google Scholar
101	Sun ML, Yang JM, Sun YP and Su GH: Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 43:219–222. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).